Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of baricitinib in adults with moderate to severe atopic dermatitis
jRCT2080223772Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2018
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing Baricitinib with Placebo (2 arms). Started Jan 2018; status: completed.
02
Drugs
baricitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080223772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223772.